Nutraceuticals: Definition and Epidemiological Rationale for Their Use in Clinical Practice. (Q38451985)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25929684%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

review article

1 reference

title

Nutraceuticals: Definition and Epidemiological Rationale for Their Use in Clinical Practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25929684%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25929684%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Roberto Volpe

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25929684%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

1 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25929684%20AND%20SRC:MED&resulttype=core&format=json

High Blood Pressure & Cardiovascular Prevention

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25929684%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25929684%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25929684%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

199-201

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25929684%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40292-015-0092-5

7 March 2020

exact match

0 references

cites work

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

The natural treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Nutraceuticals in diabetes and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Evidence of clinically relevant efficacy for dietary supplements and nutraceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Olive oil and the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Long chain omega-3 fatty acids and cardiovascular disease: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

Effect of a combined nutraceutical containing Orthosiphon stamineus effect on blood pressure and metabolic syndrome components in hypertensive dyslipidaemic patients: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40292-015-0092-5

The global cardiovascular risk chart

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Nutraceuticals for metabolic syndrome management: from laboratory to benchside

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

10.1007/S40292-015-0092-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25929684%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference